High-Grade Glioma Market

High-Grade Glioma are tumors of the central nervous system (CNS). They are solid tumors arising from transformed cells called astrocytes of the brain and/or the spinal cord.

The incidence rate of High-Grade Glioma is 5-10 new diagnoses per 1,000,000 children per year. HGGs accounts for nearly 15-20% of CNS tumours in children and adolescents. It has been observed that HGG is more common in men than in women.

The key players in the High-Grade Glioma Market includes BioMimetix, Oncoceutics, Inc., Bristol-Myers Squibb, Istari Oncology, Aadi Bioscience, Sumitomo Dainippon Pharma, Novartis, Kazia Therapeutics, and others.

For more details visit: https://www.delveinsight.com/report-store/high-grade-glioma-market